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Introduction
Fractures are associated with increased morbidity and 
mortality, and result in a considerable economic burden 
upon health care systems [1]. Although bone fragility 
and fractures have not traditionally been considered as 
major complications of type 2 diabetes mellitus, patients 
with type 2 diabetes mellitus (T2DM) are at higher risk of 
bone fragility and fractures [2] in terms of disease pathol-
ogy and associated hypoglycaemic drug therapy [3]. For 
example, thiazolidinediones (TZD) have a worldwide 
known adverse effect of increasing the fracture risk in 
postmenopausal women [4], which is recognized by doc-
tors [5]. With the increase of age and the progress of the 
disease, the probability of osteoporosis in patients with 
type 2 diabetes will increase. Therefore, we believe that it 
is necessary for individuals to carry out risk assessment 
when choosing hypoglycaemic drugs. 
As a new class of hypoglycaemic drugs, incretins are 
used increasingly in the clinic, especially for the elderly, 
because of their efficacy and safety due to their unique 
pharmacological action [6]. Incretins are a group of hor-
mones that are synthesized and secreted by gut endo-
crine cells under the stimulus of food nutrients, which 
promotes insulin secretion and inhibits inappropriate 
secretion of glucagon of alpha cells to affect the persons’ 
appetite and hypoglycaemic effect [7]. Incretins mainly 
include glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide 1 (GLP-1), which are 
rapidly metabolized by dipeptidyl peptidase 4 (DPP-4) 
in the body. The drugs are developed based on the prin-
ciple of incretins, which mainly include glucagon-like 
peptide-1 receptor agonists (GLP1-ras) and dipeptidyl 
peptidase-4 inhibitors (DPP4-Is). GLP1-ras have a sig-
nificantly extended GLP-1 half-life because they are 
not recognized by DPP-4 enzyme. And DPP4-Is can 
improve the GLP-1 level in the body by inhibiting DPP-4 
enzyme. As a result, DPP4-Is and GLP1-ras play a role 
by enhancing GLP-1 levels in the body [8]. 
The relationship between incretins and fracture is 
relatively rarely described, and data is mostly derived 
from meta-analyses. Most previous meta-analyses 
[9–14] tend to take either GLP1-ras or DPP4-Is as an ob-
ject. The mechanism of action for both GLP1-ras and 
DPP4-Is are similar in regard to GLP-1 level enhance-
ment in the body. What is more, we hope to evaluate 
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resulting discrepancies of the study selection process were resolved 
by discussion with other reviewers (BLL and LPR). The following 
information was extracted independently from eligible RCTs using 
a standardized form: trial characteristics (author’s name, year of 
publication, journal, National Clinical Trial number, study design, 
type and dose of incretins and the comparison drugs, sample size 
of the treatment and control groups, length of follow-up), and 
participants’ baseline (mean age, mean HbA1c, mean BMI, mean 
duration of diabetes) and fracture outcomes (number of fracture 
events per group, type of fracture).
Quality assessment
Three independent reviewers (QXK, QR, and CF) assessed the 
quality of the involved RCTs using the Cochrane Collaboration’s 
risk of bias tool. Quality is only seen for descriptive purposes, but 
not as the criterion for the selection of trials. The bias evaluation was 
based on all of the following seven domains: (1) random sequence 
generation (selection bias); (2) allocation concealment (selection 
bias); (3) blinding of participants and personnel (performance bias); 
(4) blinding of outcome assessment (detection bias); (5) incomplete 
outcome data (attrition bias); (6) selective reporting (reporting bias); 
and (7) other biases. For each domain, the risk of bias was divided 
into low, high, and ambiguous. Details for assessment of risk of bias 
are presented in Figure 1 and 2.
Data analysis
Trials using the Mantel-Haenszel method were pooled to calculate 
OR and 95% CIs. p values < 0.05 were considered statistically sig-
nificant. The result of the Cochrane’s Q test is the key to choosing 
the fixed or random effects model. If I2 < 50%, a fixed effects model 
was used, suggesting that there was no significant heterogeneity; 
otherwise, a random effects model was applied [17]. 
Heterogeneity evaluation was performed by the Galbraith plot, 
multiple meta-regression, and subgroup analyses. Pre-defined 
subgroup analyses were performed for trials that included differ-
ent areas (Asian vs. non-Asian); different classifications of incretins 
(DPP4-Is vs. GLP1-ras); different types of incretins (alogliptin, 
linagliptin, saxagliptin, sitagliptin, anagliptin, and vildagliptin); 
different doses of incretins [saxagliptin (2.5 mg, 5 mg, 10 mg), 
sitagliptin (25 mg, 50 mg, 100 mg), vildagliptin (50 mg, 100 mg), 
alogliptin (12.5 mg, 25 mg), linagliptin (2.5 mg, 5 mg), anagliptin 
200 mg, omarigliptin 25 mg, dulaglutide (0.75 mg, 1.5 mg), exenatide 
(30 μg, 20 μg), liraglutide (0.9 mg, 1.2 mg, 1.8 mg, 3.0 mg), lixisenatide 
20 μg, albiglutide 30 mg]; different types of control (active drug vs. 
placebo drug); different lengths of follow-up (less than 52 weeks 
vs. 52 weeks or more); mean age (less than 60 years vs. 60 years or 
more); mean HbA1c (less than 8% vs. 8% or more); mean BMI (less 
than 32 kg/m2 vs. 32 kg/m2 or more); or mean diabetes duration (less 
than 7 years vs. 7 years or more). 
Sensitivity analysis was performed to evaluate the robustness of 
the results by using different statistical models (fixed-effect model 
vs. random-effect model) and different effect measures [odds ratio 
(OR) vs. relative risk (RR)]. We also undertook the nonparametric 
“trim and fill” procedure and excluded trials with only event to fur-
ther assess the robustness in this meta-analysis. Finally, publication 
bias was investigated graphically with funnel plots. The asymmetry 
of the funnel plots was evaluated by Egger’s tests [18, 19] with p 
values < 0.10 suggesting the presence of small study effects [20, 
21]. All statistical analyses were performed with Revman (Version 
5.3) and Stata (Version 14.0).
Results  
Search results
There were 4651 unique titles and abstracts identified 
through a search of the electronic databases and the 
www.clinicaltrials.gov website. After excluding du-
whether the class of drugs increase the risk of fracture in 
the treatment of type 2 diabetes by a larger sample size, 
so it is reasonable to take incretins as the clarification. 
As the only study to take the incretins as the object, 
Driessen et al. [15] conducted a meta-analysis that 
only included four studies by searching Pubmed and 
Embase. On one hand, those four retrospective studies 
were from the same author, which may cause selection 
bias and reporting bias. On the other hand, the valid-
ity and completeness of the data in the retrospective 
primary care database will affect the correctness of the 
analysis. These may cause attrition bias. The RCT, which 
has the highest level of evidence for quality grades, ef-
fectively reduces or eliminates the imbalance between 
the treatment and control groups. Therefore, we first 
used a pool of RCT data by searching more databases 
to conduct an updated meta-analysis, in order to find 
strong evidence about the relationship between the use 
of incretins and the risk of fracture.
Material and methods
The updated meta-analysis was conducted in accordance with the 
PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement [16], and the protocol was registered at 
PROSPERO (registration number: CRD42018102261).
Data Sources and Searches
A systematic and comprehensive search of Pubmed, Embase, Web 
of Science, and the Cochrane Library was performed by three 
investigators (QXK, QR, and CF). Data were collected on all RCTs 
in humans up to December 2019. The language of the articles was 
limited to English. Differences in abstracted data between the 
reviewers were resolved by other reviewers (BLL and LPR). We 
combined both specific subject headings (e.g. MeSH terms) and 
free text terms to identify all of the potentially relevant articles in 
the databases. Considering that there were many articles about 
the efficacy and safety of drugs, it seemed inappropriate to limit 
the fracture as a search term. As a result, the search terms were 
used as follows: (1) “DPP-4”, “dipeptidyl peptidase 4”, “alogliptin”, 
“linagliptin”, “saxagliptin”, “sitagliptin”, “vildagliptin”, “glucagon 
like peptide 1”, “glucagon-like peptide-1”, “GLP-1”, “GLP 1”, “lira-
glutide”, “exenatide”, “lixisenatide”, “albiglutide”, “dulaglutide”, 
“semaglutide”; (2) “randomized”, “placebo”, and “randomized con-
trolled trial”. The trials that were completed but unpublished were 
identified through a search on the www.clinicaltrials.gov website, 
and fracture data from eligible trials were confirmed. In addition, 
we also manually searched the reference lists of the related studies 
as far as possible to identify any additional studies. 
Study selection
The trials were included if they satisfied all of the following criteria: 
(1) randomized clinical trials in type 2 diabetes patients; (2) duration 
of at least 12 weeks; (3) comparing incretins with placebo or active 
drugs; and (4) data on bone fracture available. Trials with incom-
plete original data or with 2 zero events were excluded from the 
analysis. If several studies with the same population were retrieved, 
the one with the most complete data was used.
Data extraction
Three reviewers (QXK, QR, and CF) identified studies and indepen-
dently abstracted data according to the predefined protocol. Any 
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plicate publications and screening titles and abstracts, 
we retrieved 2541 reports for full text evaluation. As 
a result, 110 randomized control trials (RCTs), includ-
ing 74 from electronic database and 36 from the trial 
registry (available from https://clinicaltrials.gov) met 
the inclusion criteria. The details of the study selection 
flow are summarized in Figure 1.
Study characteristics
The baseline characteristics of trials are listed in Table 1. 
Out of these 110 RCTs, a total of 12 drug subjects were 
included, of which NCT00295633, NCT00294723, 
NCT00856284,  NCT00121667,  NCT00722371, 
NCT01272219,  NCT00103857,  NCT01075282, 
NCT01191268, and NCT01621178 were compared 
with different doses. Among them, NCT00121667 and 
NCT00722371 made a comparison of three doses, and 
the rest made a comparison of two doses. Therefore, 
122 trials were included in this meta-analysis, with 96 
double-blind trials. The final sample consisted of 111,539 
individuals (58,706 individuals were in the experimental 
group and 52,833 individuals were in the control group), 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Low risk of bias Unclear risk of bias High risk of bias
0%                  25%                 50%                 75%               100%
Figure 2. “Risk of bias” summary: review authors’ judgements about each risk of bias item for each included study
Medline/Embase/Cochrane/Clinicaltrials.gov/manual search 
4651 potentially relevant studies
2110 excluded based on duplicate checking by computer
2541 retrieved for detailed evaluation
2431 excluded based on detailed evaluation
842 review or meta-analysis 
236 no T2DM
282 no DPP-4i or GLP-1Ra
362 no RCT
84 study duration < 12 weeks
492 no disclosure of bone events
72 duplicate study
14 comparison with another DPP-4i or GLP-1Ra
37 conference or case report
10 animal trials
 110 included in systematic review
Figure 3. Study selection process; T2DM — diabetes mellitus; DPP-4 — dipeptidyl peptidase 4; GLP — glucagon-like peptide; 
RCT — randomized control trial
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Table 1. Subgroup analyses of changes
Group Number of study WMD
Net change  
(95% CI) p-value Pheterogeneity I
2
DPP-4/GLP-1
Vildagliptin 6 0.859 0.287–2.566 0.785 0.656 0.0%
Sitagliptin 33 0.913 0.758–1.100 0.340 0.969 0.0%
Exenatide 9 1.872 0.901–3.892 0.093 0.817 0.0%
Saxagliptin 14 0.995 0.838–1.182 0.956 0.357 0.0%
Alogliptin 8 0.807 0.562–1.158 0.244 0.929 0.0%
Liraglutide 11 0.714 0.499–1.023 0.067 0.483 0.0%
Linagliptin 17 1.408 0.859–2.306 0.175 0.965 0.0%
Lixisenatide 8 1.154 0.511–2.606 0.730 0.903 0.0%
Albiglutide 2 2.668 0.291–24.490 0.386 0.918 0.0%
Dulaglutide 10 1.051 0.532–2.078 0.886 0.589 0.0%
Omarigliptin 3 1.509 0.765–2.973 0.235 0.620 0.0%
Anagliptin 1 8.217 0.410–164.684 0.168 0.000 0.0%
Incretins
DPP-4 82 0.977 0.873–1.095 0.692 0.993 0.0%
GLP-1 40 0.944 0.722–1.234 0.672 0.835 0.0%
Comparator
Placebo 63 0.973 0.870–1.089 0.638 0.925 0.0%
Active drug 59 0.966 0.734–1.272 0.806 0.985 0.0%
Region
Asian 17 1.105 0.609–2.004 0.743 0.736 0.0%
Non-Asian 58 0.990 0.859–1.156 0.894 0.943 0.0%
Age [y]
≥ 60 24 0.954 0.848–1.073 0.432 0.576 0.0%
< 60 93 1.015 0.808–1.276 0.896 0.995 0.0%
BMI [kg/m2]
≥ 32 24 0.976 0.647–1.473 0.909 0.747 0.0%
< 32 55 0.947 0.819–1.095 0.458 0.984 0.0%
Length of follow-up [y]
≥ 52 59 0.967 0.865–1.080 0.551 0.875 0.0%
< 52 63 1.014 0.748–1.376 0.928 0.993 0.0%
Duration [y]
≥ 7 30 0.960 0.849–1.087 0.523 0.968 0.0%
< 7 29 0.819 0.565–1.188 0.294 0.767 0.0%
HbA1c (%)
≥ 8 58 0.896 0.777–1.034 0.132 0.972 0.0%
< 8 29 1.060 0.885–1.270 0.529 0.909 0.0%
Dose
Albiglutide 30 mg 2 2.668 0.291–24.490 0.386 0.918 0.0%
Alogliptin 12.5 mg 1 0.744 0.166–3.334 0.699 0.000 0.0%
Alogliptin 25 mg 65 0.994 0.458–2.157 0.989 0.838 0.0%
Anagliptin 200 mg 1 8.217 0.410–164.684 0168 0.000 0.0%
Dulaglutide  0.75 mg 4 0.869 0.302–2.498 0.794 0.464 0.0%
Dulaglutide 1.5 mg 6 1.206 0.491–2.962 0.684 0.423 0.0%
Exenatide 30 ug 1 3.000 0.122–74.025 0.502 0.000 0.0%
Exenatide 20 ug 7 1.662 0.759–3.639 0.204 0.703 0.0%
Linagliptin 2.5 mg 2 0.881 0.123–6.294 0.900 0.877 0.0%
Linagliptin 5 mg 15 1.452 0.871–2.420 0.153 0.929 0.0%
Liraglutide 0.9 mg 1 0.166 0.007–4.096 0.272 0.000 0.0%
Liraglutide 1.2 mg 2 0.552 0.117–2.606 0.453 0.170 47.0%
Liraglutide 1.8 mg 4 0.621 0.413–0.933 0.022 0.748 0.0%
Liraglutide 3.0 mg 3 3.964 0.885–17.753 0.072 0.983 0.0%
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of whom 1265 individuals had fractures (628 individu-
als were in the experimental group and 637 individuals 
were in the control group).
The age of the included patients ranged from 49.4 to 
71.6 years. The length of follow-up period ranged from 
12 to 234 weeks. The sample sizes of individual trials 
were between 21 and 16,492 patients. Among all of the 
patients included, the mean HbA1c was 7.96 ± 1.10%, 
mean BMI was 30.59 ± 3.75 kg/m2, and mean duration 
of diabetes was 7.89 ± 3.92 years. Fifty-nine trials were 
placebo-controlled, and 63 trails used an active com-
parator, which included canagliflozin, empagliflozin, 
dapagliflozin, glipizide, glimepiride, metformin, vogli-
bose, insulin, and pioglitazone. 
Odds ratio of fracture
The fixed-effects model was used on account of the 
I2 test for heterogeneity (I2 = 0.0%). The pooled 
OR of fracture for patients treated with incretins 
versus controls was 0.97 (95% CI: 0.88–1.08), which 
showed that incretins did not enhance the risk of 
fracture (Fig. 4). The pooled OR of fracture patients in 
DPP4-Is and GLP1-ras were 0.98 [0.87–1.10] and 0.94 
[0.72–1.23], respectively (Tab. 1). Subgroup analysis 
was performed to explore which factors had an ef-
fect on the OR of fractures with incretins, whereas 
p values of most of the subgroup analysis (different 
areas; different classification of incretins; different 
types of incretins; different doses of incretins; differ-
ent types of control; different lengths of follow-up; 
mean age; mean HbA1c ; mean BMI; mean diabetes 
duration) were greater than 0.05. The only signifi-
cant difference was observed in the different doses 
of incretins when the subgroups were stratified by 
sitagliptin 100 mg and liraglutide 1.8 mg (p = 0.005 
and p = 0.022, respectively). The fractures occurred 
mainly in NCT00968708, NCT00295633, NCT01107886, 
NCT00790205, NCT01703208, NCT01179048, and 
NCT01272219, as shown in Supplementary File 
— Table S1.
Publication bias
Based on Egger’s test (p = 0.735) and visual inspec-
tion, the asymmetrical funnel plot indicated no major 
publication bias (Fig. 5). 
Heterogeneity analysis
No heterogeneity was observed among these studies 
(I2 = 0.0%, p = 0.996). As can be seen from the Galbraith 
plot, compared to other trials, the heterogeneity of 
NCT01179048 and NCT00295633 is significant. Multiple 
meta-regression was performed with p values of co-
variate (classification of incretins, type of experimental 
drugs, type of control drugs, experimental group dose, 
region, age, BMI, intervention time, diabetes duration, 
glycosylated haemoglobin) were greater than 0.1, 
indicated none of these factors contribute to heteroge-
neity. Meanwhile, subgroup analyses based on study 
characteristics were performed to further explore pos-
sible sources of heterogeneity. In addition to liraglutide 
1.2 mg and saxagliptin 5 mg (I2 = 47.0%, I2 = 33.7%), 
other’s heterogeneity is 0.0%. The heterogeneity is ac-
ceptable if it is less than 50%.
Sensitivity analysis
The multiple sensitivity was analysed to evaluate the 
robustness of results among studies. These were based on 
the following: (1) selection of different effect models; (2) 
selection of different effect sizes; (3) trim and fill method; 
and (4) investigating the effect of a single trial on the 
whole. The results showed that the selection of differ-
ent effect models (random-effect model, MH-OR 0.971, 
95% CI: 0.872–1.082) and different effect sizes (MH-RR 
0.973, 95% CI: 0.878–1.077) had no obvious effect on the 
Table 1. Subgroup analyses of changes
Group Number of study WMD
Net change  
(95% CI) p-value Pheterogeneity I
2
Dose
Omarigliptin 25 mg 2 1.453 0.724–2.914 0.293 0.387 0.0%
Saxagliptin 10 mg 2 3.329 0.376–29.459 0.280 0.933 0.0%
Saxagliptin 2.5 mg 4 1.844 0.584–5.821 0.297 0.662 0.0%
Saxagliptin 5 mg 8 0.970 0.814–1.155 0.729 0.159 33.7%
Sitagliptin 100 mg 29 0.495 0.304–0.806 0.005 0.998 0.0%
Sitagliptin 25 mg 1 5.240 0.247–111.319 0.288 0.000 0.0%
Sitagliptin 50 mg 1 0.317 0.013–7.841 0.483 0.000 0.0%
Vildagliptin 100 mg 3 0.566 0.120–2.678 0.473 0.455 0.0%
Vildagliptin 50 mg 3 1.370 0.270–6.952 0.704 0.537 0.0%
DPP-4 — dipeptidyl peptidase 4; GLP-1 — glucagon-like peptide 1 WMD — weighted mean difference; BMI — body mass index; CI — confidence interval
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effect altered from (OR: –0.029, 95% CI: –0.137–0.079) 
to (OR: –0.042, 95% CI: –0.150–0.065). There was no 
conclusion, and the results were stable. Five trials with 
unclear risk of bias were excluded, and the combined 
 






MH fixed OR 
(95% CI)
Study/Subgroup No of events/total 
Incretin Control Control




MH fixed OR 
(95% CI)
Bosi 2009 1/292 0/292 0.07 3.01 (0.12 to 74.20) NCT00838916 2/504 0/241 0.09 2.40 (0.12 to 50.25)
Iwamoto(a) 2010 0/163 1/156 0.21 0.32 (0.01 to 7.84) NCT00849017 1/101 0/101 0.07 3.03 (0.12 to 75.26)
Iwamoto(b) 2010 0/188 2/192 0.34 0.20 (0.01 to 4.24) NCT00856284(a) 3/885 4/874 0.56 0.74 (0.17 to 3.32)
NCT00082381 0/282 1/267 0.21 0.31 (0.01 to 7.75) NCT00856284(b) 3/880 4/874 0.56 0.74 (0.17 to 3.33)
NCT00082407 1/253 0/248 0.07 2.95 (0.12 to 72.82) NCT00866 658 1/154 1/157 0.14 1.02 (0.06 to 16.45)
NCT00086502 0/175 1/178 0.21 0.34 (0.01 to 8.33) NCT00881530 0/56 1/56 0.21 0.33 (0.01 to 8.21)
NCT00086515 0/464 1/237 0.28 0.17 (0.01 to 4.18) NCT00885352 0/157 1/156 0.21 0.33 (0.01 to 8.14)
NCT000 87516 0/238 1/130 0.27 0.18 (0.01 to 4.48) NCT00915772 1/225 1/170 0.16 0.75 (0.05 to 12.15)
NCT00094770 3/588 3/584 0.42 0.99 (0.2 to 4.94) NCT00935532 2/215 0/212 0.07 4.98 (0.24 to 104.28)
NCT00099931 0/144 1/152 0.20 0.35 (0.01 to 8.65) NCT00954447 5/631 6/630 0.83 0.83 (0.25 to 2.74)
NCT00101712 0/156 1/150 0.21 0.32 (0.01 to 7.88) NCT00960661 2/315 0/312 0.07 4.98 (0.24 to 104.24)
NCT00103857(a) 0/179 1/182 0.21 0.34 (0.01 to 8.33) NCT00968708 38/2676 50/2698 6.85 0.76 (0.5 to 1.17)
NCT00103857(b) 0/179 2/182 0.34 0.20 (0.01 to 4.22) NCT01006603 9/359 4/359 0.54 2.28 (0.7 to 7.48)
NCT00121667(a) 1/181 0/179 0.07 2.98 (0.12 to 73.72) NCT01012037 3/447 0/44 0.13 0.70 (0.04 to 13.79)
NCT00121667(b) 1/191 0/179 0.07 2.83 (0.11 to 69.84) NCT01023581 0/445 1/334 0.24 0.25 (0.01 to 6.15)
NCT00121667(c) 2/192 0/179 0.07 4.71 (0.23 to 98.81) NCT01075282(a) 1/273 0/262 0.07 2.89 (0.12 to 71.26)
NCT00286468 1/198 0/99 0.09 1.51 (0.06 to 37.44) NCT010 75282(b) 1/272 0/262 0.07 2.90 (0.12 to 71.52)
NCT00294723(a) 2/251 1/248 0.14 1.98 (0.18 to 22.02) NCT01076075 0/210 1/212 0.21 0.34 (0.01 to 8.27)
NCT00294723(b) 0/246 1/248 0.21 0.34 (0.01 to 8.26) NCT01076088 0/247 3/250 0.48 0.14 (0. 01 to 2.78)
NCT00295633(a) 4/195 2/184 0.28 1.91 (0.35 to 10.53) NCT01084005 2/162 0/79 0.09 2.48 (0.12 to 52.2)
NCT00295633(b) 1/186 11/184 1.53 0.09 (0.01 to 0.67) NCT01106677 0/368 2/366 0.35 0.20 (0.01 to 4.14)
NCT00305604 0/102 2/104 0.34 0.20 (0.01 to 4.22) NCT01106690 0/115 1/113 0.21 0.33 (0.01 to 8.05)
NCT00313313 1/248 0/267 0.07 3.24 (0.13 to 79.97) NCT01107886 241/8280 240/8212 32.63 1.00 (0.83 to 1.19)
NCT00327015 3/643 0/328 0.09 3.59 (0.19 to 69.71) NCT01126580 1/269 0/268 0.07 3.00 (0.12 to 73.97)
NCT00328627 0/129 1/129 0.21 0.33 (0.01 to 8.2) NCT01137812 1/378 2/377 0.28 0.50 (0.05 to 5.51)
NCT00337610 0/96 1/94 0.21 0.32 (0.01 to 8.03) NCT01177813 0/223 1/224 0.21 0.33 (0.01 to 8.23)
NCT0 0350779 0/170 1/92 0.27 0.18 (0.01 to 4.44) NCT01179048 35/4668 58/4672 8.02 0.60 (0.39 to 0.92)
NCT00359762 7/508 5/511 0.69 1.41 (0.45 to 4.49) NCT01183013 1/133 0/140 0.07 3.18 (0.13 to 78.78)
NCT00372060 0/66 1/68 0.20 0.34 (0.01 to 8. 46) NCT01191268(a) 2/295 3/296 0.41 0.67 (0.11 to 4.02)
NCT00395343 1/322 0/319 0.07 2.98 (0.12 to 73.46) NCT01191268(b) 3/293 3/296 0.41 1.01 (0.20 to 5.05)
NCT00397631 1/261 0/259 0.07 2.99 (0.12 to 73.7) NCT01204294 1/228 0/124 0.09 1.64 (0.07 to 40.60)
NCT00411554 0/155 1/147 0.21 0.31 (0.01 to 7.77) NCT01215097 1/205 0/100 0.09 1.47 (0.06 to 36.51)
NCT00432276 6/404 4/399 0.55 1.49 (0.42 to 5.32) NCT01272219(a) 4/957 0/487 0.09 4.6 (0.25 to 85.64)
NCT00434954 3/247 0/233 0.07 6.69 (0.34 to 130.12) NCT01272219(b) 8/1524 1/755 0.19 3.98 (0.5 to 31.87)
NCT00449930 1/455 0/439 0.07 2.90 (0.12 to 71.4) NCT01272232 1/210 0/212 0.07 3.04 (0.12 to 75.12)
NCT00482729 1/625 2/621 0.28 0.50 (0.05 to 5.48) NCT01289 990 0/223 2/168 0.40 0.15 (0.01 to 3.12)
NCT00509236 2/64 0/65 0.07 5.24 (0.25 to 111.32) NCT01296412 0/324 3/326 0.49 0.14 (0.01 to 2.77)
NCT00509262 1/211 1/212 0.14 1.01 (0.06 to 16.17) NCT01388361 0/87 1/86 0.21 0.33 (0.01 to 8.11)
N CT00516074 1/28 0/26 0.07 2.89 (0.11 to 74.17) NCT01422876 0/267 1/276 0.21 0.34 (0.01 to 8.47)
NCT00575588 4/428 2/430 0.28 2.02 (0.37 to 11.08) NCT01438814 0/344 1/345 0.21 0.33 (0.01 to 8.21)
NCT00601250 1/523 0/177 0.10 1.02 (0.04 to 2 5.13) NCT01462266 0/329 1/329 0.21 0.33 (0.01 to 8.19)
NCT00602472 3/792 0/263 0.10 2.34 (0.12 to 45.38) NCT01512108 0/240 1/120 0.28 0.17 (0.01 to 4.10)
NCT00614939 0/85 1/85 0.21 0.33 (0.01 to 8.20) NCT01557166 1/176 0/179 0.07 3.07 (0. 12 to 75.83)
NCT00621140 1/336 2/167 0.37 0.25 (0.02 to 2.74) NCT01584232 1/181 0/180 0.07 3.00 (0.12 to 74.13)
NCT00622284 9/776 4/775 0.55 2.26 (0.69 to 7.38) NCT01606007 1/176 0/179 0.07 3.07 (0.12 to 75.83)
NCT00661362 3/283 0/287 0.07 7.18 (0.37 to 139.53) NCT01617434 1/225 1/225 0.14 1.00 (0.06 to 16.09)
NCT00688701 0/239 1/122 0.28 0.17 (0.01 to 4.18) NCT01621178(a) 0/190 3/194 0.48 0.14 (0.01 to 2.80)
NCT00701090 2/516 1/519 0.14 2.02 (0.18 to 22.30) NCT01621178(b) 0/192 3/194 0.48 0.14 (0.01 to 2.77)
NCT00707993 2/222 1/219 0.14 1.98 (0.18 to 22.02) NCT01697592 2/191 0/196 0.07 5.19 (0.25 to 108.7)
NCT00712673 5/510 0/170 0.10 3.71 (0.2 to 67.45) NCT01698775 1/106 0/106 0.07 3.03 (0.12 to 75.19)
NCT0 0713830 4/574 1/285 0.19 1.99 (0.22 to 17.91) NCT01703208 17/2100 13/2102 1.80 1.31 (0.64 to 2.71)
NCT00715624 2/328 1/167 0.18 1.02 (0.09 to 11.31) NCT01769378 1/239 0/60 0.11 0.76 (0.03 to 18.91)
NCT00722371(a) 1/231 1/230 0.14 1.00 (0.06 to 16.01) NCT01792518 1/182 0/178 0.07 2.95 (0.12 to 72.91)
NCT00722371(b) 1/231 1/233 0.14 1.01 (0.06 to 16.22) NCT01798706 2/176 1/174 0.14 1.99 (0.18 to 22.13)
NCT00722371(c) 1/231 0/230 0.07 3.00 (0.12 to 74.03) NCT02002221 1/78 0/78 0.07 3.04 (0.12 to 75.75)
NCT00757588 2/304 3/151 0.56 0.33 (0.05 to 1.98) NCT02058147 0/233 1/467 0.14 0.67 (0.03 to 16.41)
NCT00763451 3/322 2/160 0.37 0.74 (0.12 to 4.49) NCT02104804 1/234 2/231 0.28 0.49 (0.04 to 5.46)
NCT00765817 0/137 1/122 0.22 0.30 (0.01 to 7.30) NCT02152371 4/150 0/150 0.07 9.25 (0.49 to 173.25)
NCT00790205 189/7332 186/7339 25.26 1.02 (0.83 to 1.25) NCT02229383 1/232 0/231 0.07 3.00(0.12 to 74.03)
NCT00798161 1/143 1/147 0.14 1.03 (0.06 to 16.6) Pan 2012 1/148 0/144 0.07 2.94 (0.12 to 72.74)
NCT00800683 2/68 0/65 0.07 4.93 (0.23 to 104.56) Yang 2015 3/37 0/40 0.06 8.22 (0.41 to 164.68)
Total (95% CI) 628/58706 637/52833 100.00 0.97 (0.88 to 1.08)
0.1     1    100 0.1 1 100
Favours incretins Favours control Favours incretins Favours control
Heterogeneity: c2 = 83.97, df = 121, p = 0.996, I2 = 0.0%
Test for OR = 1: z = 0.53, p = 0.597
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ment with incretins. We know that GLP-1 can reduce 
the risk of fracture, mainly related to increasing bone 
mass, improving trabecular and cortical architectures, 
enhancing bone strength and tissue material properties, 
and affecting the collagen compartment rather than 
the mineral one. Moreover, the effect of liraglutide on 
bone may be increased by osteoblastic markers such as 
Runx2, α-1 coll, and ALP [11, 24]. Some research showed 
that liraglutide is widely used all over the world, and it 
shares 97% sequence identity with native GLP-1 [25, 26]. 
Therefore, we hypothesized that the probable reason 
for liraglutide reducing the fracture risk is similar to 
that for GLP-1.
We have confirmed for the first time that sitagliptin 
100 mg (OR: 0.495, 95% CI: 0.304–0.806) has a protective 
effect on fracture by meta-analysis. Sitagliptin is the first 
DPP-4 inhibitor to be used in clinical practice. Cusick et 
al. [27] proved in diabetic rats that sitagliptin probably 
reduced the bone resorption marker cyclophosphamide 
and attenuated bone loss to increase bone strength in-
dependently of the hypoglycaemic effect. Similarly, in 
clinical studies, Hegazy et al. [28] showed that after 12 
weeks, compared with metformin treatment, sitagliptin 
treatment led to a slight increase in bone transforma-
tion markers and bone mineral density in the vertebrae. 
This may partly explain why sitagliptin 100 mg showed 
positive effects in our meta-analysis, with a reduced 
risk of fracture.
Although the differences of other subgroup analy-
ses (mean BMI; different lengths of follow-up; differ-
significant change before and after the pruning, and the 
results were stable. In addition, the effect of a single trial 
on the combined effect was investigated. It was found 
that a single study has little effect on the combined effect.
Quality of evidence
The quality assessment of the 122 trials is summarized 
in Figure 2–3. Among these trials, 70 (57.4%) adequately 
generated their randomization sequence, 97 (79.5%) 
concealed allocation, 101 (82.8%) blinded participants 
and personnel, 62 (50.8%) blinded outcome assessment, 
and 111 (92.5%) reported complete outcome data.
Discussion
Our meta-analysis showed that the use of incretins 
did not enhance the fracture risk (OR: 0.972, 95% CI: 
0.876–1.079) compared with placebo or other active 
drugs. Also, in subgroup analysis, we found that the 
dose administered in groups of sitagliptin 100 mg (OR: 
0.495, 95% CI: 0.304–0.806) and liraglutide 1.8 mg (OR: 
0.621, 95% CI: 0.413–0.933) can reduce the risk of frac-
ture. No other subgroups were found to either reduce 
or increase the risk of fracture.
In subgroup analysis, it was not the first discovery 
that the dose administered in groups of liraglutide 
1.8 mg (OR: 0.621, 95% CI: 0.413–0.933) can reduce the 
risk of fracture [22, 23]. However, we still know little 
about the interpretation of how to decrease fracture 
risk among T2DM patients during subsequent treat-
Figure 5. The results of funnel plots (A), Galbraith plot (B), sensitivity analysis and trim (C), and fill plot (D) of the use of incretins 














of fracture of the drug may be confirmed by long-term 
clinical data. In addition, the included studies lacked 
a record of the subjects’ lifestyle, physical activity, smok-
ing, drinking, etc., and if there are differences in these 
factors in the experimental group and control group, it 
may lead to biased results regarding the effect on frac-
ture [31]. Moreover, the included studies were mostly 
based on HbA1c and cardiovascular events as primary 
outcome measures, but fracture events were ignored 
and not reported as adverse events which may be one 
of the reasons why our results are negative.
The above reason may cause including studies only 
partially reflected the occurrence of the drug-induced 
fracture events [32]. But in TECOS, fractures occurred 
at a rate of 9/1000 per year [33]. Hence, the skeletal 
safety profiles of diabetic medications deserve attention, 
and further investigation is necessary. Considering the 
limitations of existing RCT trials, we suggest consider-
ing the following four aspects. Firstly, fracture events 
should be taken as the main study endpoint. In order 
to ensure patient level consistency, the recording of 
patients’ basic information is necessary. In addition, 
fracture evaluation methods should include the bone 
mineral density and bone metabolism indicators, etc. 
What is more, sufficiently long follow-up events are 
also essential, which can clearly explain the association. 
Conclusions
This meta-analysis suggested that current use of in-
cretins does not increase the risk of fracture in type 2 
diabetes patients from RCT studies. It also showed 
a protective effect on bone metabolism when sitagliptin 
100 mg or liraglutide 1.8 mg/day was administrated. 
Therefore, we believe that the use of incretins does 
not increase the risk of fracture when used in patients 
with T2DM. In addition, we consider that older patients 
are prone to osteoporosis, so we suggest that these 
people be treated with hypoglycaemic therapy with 
drugs such as sitagliptin or liraglutide, which may have 
bone-protective effects.
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ent areas; different types of control; mean age; mean 
HbA1c; mean diabetes duration) were not statistically 
significant, it was meaningful to conduct subgroup 
analysis. For example, it is well known that BMI is 
positively correlated with bone mineral density and 
negatively correlated with the incidence of osteopo-
rosis, which is a protective factor for bone mineral 
density [29]. Therefore, the effect of drugs on patients’ 
BMI may have different effects on fracture outcome. 
Incretin users are generally overweight, and weight 
loss-induced bone mass decreases after using incre-
tins, both of which may weaken the positive effect of 
incretins on bone metabolism, resulting in a neutral 
result of the fracture risk after incretin treatment in 
clinical trials. The fracture risk in thiazolidinediones 
(TZD) users was not exposed in the preclinical study, 
registration, and listing research. The risk of fractures 
was revealed after the five-year follow-up [30]. Different 
follow-up times may affect the outcome of the study, so 
we conducted subgroup analysis on the follow-up time. 
Although we did not draw conclusions on the effect of 
follow-up time of incretins on fractures, we can explore 
the association between incretin use and fracture risk 
during long duration incretin therapy. 
Although HbA1c had no significant difference in 
our subgroup analysis results, according to relevant 
studies, excessive blood sugar can form glycation end 
products (AGEs) with proteins, amino acids, peptides, 
and nucleic acids in the body. AGE accumulation can re-
duce bone strength, inhibit the expression of osteoblast 
phenotype, and promote osteoblast apoptosis, which 
leads to insufficient bone formation [24]. Thus, we still 
believe that positively alleviating the toxicity of high 
glucose and relieving the damage of bones caused by 
high glucose toxicity is beneficial to bone metabolism.
The advantages of this article are the first inclu-
sion of RCT research data in cohort studies and that 
GLP1-ras and DPP4-Is are used as research objects 
for meta-analysis. Secondly, through a scientific and 
rigorous retrieval process as well as careful screen-
ing, our meta-analysis sample size was the largest, 
involving a total of 122 trials studies with 40 studies for 
GLP1-ras and 82 studies for DPP4-Is including 111,539 
patients. Furthermore, it was the most comprehensive 
meta-analysis of the data, and we conducted multilevel 
subgroup analysis. Finally, our results not only proved 
to be robust through a variety of sensitivity analysis 
methods, but also no major publication and no hetero-
geneity was observed among these studies.
The disadvantages of this article are that the 
follow-up time in these studies is relatively short (the 
length of follow-up period ranged from 12 to 234 
weeks). As TZD drugs, the risk of fractures was revealed 
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